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Abstract
Background: Gastric cancer is one of the most common malignancies worldwide. Recent studies have shown that
microRNAs play crucial roles in regulating cellular proliferation process in gastric cancer. MicroRNA-29c (miR-29c)
acts as a tumor suppressor in different kinds of tumors.
Methods: Quantitative PCR was performed to evaluate miR-29c expression level in 67 patient gastric cancer tissues
and 9 gastric cancer cell lines. The effects of miR-29c were explored by proliferation assay, soft agar colony formation
assay, apoptosis and cell cycle analysis using flow cytometry. The target gene was predicted by bioinformatic
algorithms and validated by dual luciferase reporter assay and Western blot analysis.
Results: In this study, we demonstrate that miR-29c is down-regulated in gastric cancer tissues and cell lines. We
indicate that overexpression of miR-29c inhibits cell proliferation, promotes apoptosis and arrests cell cycle at G1/G0
phase. We additionally show that miR-29c exerts these effects by targeting Nuclear autoantigenic sperm protein
(NASP). Moreover, depletion of NASP can elite the phenotypes caused by miR-29c.
Conclusions: These data suggest that miR-29c inhibits proliferation in gastric cancer and could potentially serve as an
early biomarker and a novel therapy target.
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Background
Gastric cancer is the fifth most common malignancy and
the third leading cause of cancer-related deaths, accord-
ing to the GLOBOCAN series of the International
Agency for Research on Cancer [1]. Surgery is the only
curative treatment, however, many patients have inoper-
able disease at diagnosis or have recurrent disease after
resection [2]. Therefore, it is crucial to elucidate the mo-
lecular mechanisms underlying the development of gas-
tric cancer and to look for new molecular markers and
therapeutic targets.
MicroRNAs (miRNAs) are a class of small, non-coding
RNAs about 18–25 nucleotides in length. MiRNAs
mainly function to negatively regulate gene expression
by promoting mRNA degradation or inhibiting mRNA
translation through interacting with perfect or imperfect
complementary sequences between the miRNA seed and
the 3′untranslated regions (3′UTR) of its target genes
[3]. MiR-29c belongs to the miR-29 family, which is
composed of four species with identical seed sequences,
namely miR-29a, miR-29b-1, miR-29b-2 and miR-29c
[4]. MiR-29c plays the role as tumor suppressor in sev-
eral kinds of tumors. MiR-29c was shown to inhibit cell
growth, cell migration and invasion in pancreatic cancer
by targeting ITGB1 [5]. In bladder cancer, miR-29c over-
expression inhibited cell growth, suppressed cell migra-
tion and resulted in an accumulation of cells in the G1
phase during the cell cycle through the target gene
CDK6 [6]. MiR-29c was displayed to mediate the epithe-
lial to mesenchymal transition (EMT) and negatively
regulated Wnt/β-catenin signaling pathway via PTP4A
and GNA13 in human colorectal carcinoma [7]. MiR-
29c down-regulation by CpG dinucleotide methylation of
the promoter has been participated in cell invasion and in-
creased sensitive to chemotherapy in basal-like breast tu-
mors [8]. Further studies on liver carcinoma that focused
on the suppressive role of ionizing radiation-responsive
miR-29c in the development of the disease via targeting
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WIP1 [9]. In lung cancer, miR-29c was shown to suppress
cell adhesion and metastasis by targeting integrin β1 and
MMP2 [10].
In the present study, we qualified the expression of
miR-29c in gastric cancer tissues and evaluated its role
in cell proliferation and induction of cell apoptosis. We
found that miR-29c has a general decrease in gastric can-
cer tissues compared with the matched normal tissues.
Overexpression of miR-29c reduced cell proliferation by
promoting apoptosis and inducing cell cycle G1/G0 arrest
in vitro, and inhibited the ability of tumorigenesis in gas-
tric cancer cells in vivo. Furthermore, we demonstrated
that miR-29c can decrease NASP expression and the ef-
fects observed following miR-29c overexpression are par-
tially due to NASP depletion. Thus, all of these results
suggest that miR-29c is a potential marker for diagnose
and therapeutic target for treatment in gastric cancer.
Methods
Human samples
Sixty-seven pairs of tumor tissues and paired adjacent
normal tissues were collected from patients with gastric
cancer who underwent surgery at the Department of
Surgery, Ruijin Hospital, Shanghai Jiao Tong University
School of Medicine. All samples were diagnosed by
pathological examination, clinicopathological data were
reviewed and TNM staging classification was ranked
base on criteria of American Joint Committee on Cancer
(AJCC, 6th edition).
Cell lines
The human gastric cancer cell lines SNU-1 (ATCC No.
CRL-5971), SNU-16 (ATCC No. CRL-5974), NCI-N87
(ATCC No. CRL-5822), AGS (ATCC No. CRL-1739)
and KATOIII (ATCC No. HTB-103) were got from the
American Type Culture Collection, MKN-45 (JCRB No.
0254) and MKN-28 (JCRB No. 0253) were obtained
from the Japanese Cancer Research Resources Bank, and
the others (BGC-823: CBP60477, SGC-7901: CBP60500)
were obtained from Shanghai Institute for Biological
Sciences, Chinese Academy of Science. The immortal-
ized normal gastric mucosal epithelial cell line (GES-1)
and the human embryonic kidney cell line 293 T (HEK
293 T) were preserved in our institute. Gastric cancer
cell lines were cultured in RPMI-1640, while HEK 293 T
cells were cultured in DEME, supplemented with 10%
heat-inactivated fetal calf serum with 100 U/ml penicillin
and 100 μg/ml streptomycin at 37 °C in a humidified at-
mosphere of 5% CO2. Exponentially growing cells were
used for experiments.
RNA extraction and quantitative PCR (qPCR)
Total RNA isolation from homogenized tissue samples and
cell lines was performed using Trizol reagent (Invitrogen,
Carlsbad, CA, USA) and reverse transcribed into cDNA
using the miScript II RT Kit (Qiagen, Venlo, Limburg,
Netherlands). MiR-29c qPCR was assayed by All-in-One
qPCR Mix Kit (GeneCopoeia, Rockville, MD, USA) with
specific primer on ABI 7900 system. Expression of miR-
29c was normalized to U6 small nuclear RNA and analyzed
by the 2-ΔΔCt method. NASP mRNA expression level was
measured by SYBR Green real time PCR (Applied Biosys-
tems, Foster City, CA, USA) following the manufacturer’s
instructions. GAPDH was used as an internal control. Fol-
lowing primers were used: NASP sense 5′- GCGTCCCA
AATTGCCTGTTT -3′ antisense 5′- GCTTCACTATCC




Oligonucleotides hsa-miR-29c mimics (miR-29c), miR-
control and siRNAs for NASP were purchased from
GenePharma (Shanghai, China). Oligonucleotides and
siRNAs were transfected into cells by carring out with
Lipofectamine 2000 (Invitrogen) at a final concentration
of 100 nM. The transfection efficiency was monitored by
qPCR or Western blot.
Cell proliferation assay
Cell proliferation was accessed by colorimetric water-
soluble tetrazolium salt (WST) method using the Cell
Counting Kit-8 (Dojindo, Kumamoto, Japan) according
to the manufacturer’s instructions. After 24 h, cells
transfected with miR-29c mimics or NASP siRNA were
seeded into 96-well plates (2 × 103 cells/well), and the
proliferation was monitored everyday for 5 days. The
number of viable cells was determined by measurement
of the absorbance at 450 and 600 nm using a Safire 2
microplate reader (TECAN, Switzerland).
Soft agar colony formation assay
Cells transfected with miR-29c mimics were resus-
pended with 0.3% soft agar in RPMI-1640 containing
10% FBS, then layered onto 0.6% solidified agar in
RPMI-1640 containing 10% FBS in 6-well plates (1 × 103
cells/well) at 24 h post-transfection. These plates were
incubated at 37 °C for 2 weeks. Colonies containing 50
cells or more were counted.
Apoptosis analysis
Cells transfected with miRNA or siRNA were harvested
at 48 h after transfection cells and stained with Annexin
V-FITC Apoptosis Detection Kit I (BD Pharmingen, CA,
USA). Apoptotic cells were assessed in triplicates and re-
peated three times independently by flow cytometry
(FACS Calibur, Becton Dickinson, NJ, USA).
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Cell cycle analysis
At 48 h post-transfection with miRNA or siRNA, cells
were fixed overnight using 70% ethanol at 4 °C, washed
two times in cold phosphate-buffered saline, and incu-
bated with 100 μg/ml RNase A and 50 μg/ml propidium
iodide for 1 h at 37 °C. Analysis was performed on a
FACS Calibur flow cytometry by measurement of the
percentage of cells in various phases of the cell cycle.
Construction of plasmids and luciferase activity assay
Wild type NASP-3′ UTR or mutant NASP-3′ UTR con-
taining the putative miR-29c binding sites were synthesized
by Sangon, Shanghai, China. After digestion by MluI and
SpeI, wild type and mutant NASP-3′ UTR were cloned
into the MluI and SpeI precut pMIR-Report luciferase vec-
tor. In HEK 293 T cells pre-seeded 24-well, 100 ng pMIR/
NASP-WT or MUT, together with 2 ng pRL-TK vector
containing Renilla luciferase and 100 nM miR-29c mimics
or miR-control were cotransfected by Lipofectamine 2000
(Invitrogen). After 48 h, relative luciferase activity was
measured by dual-luciferase assay (Promega, Madison, WI,
USA) according to the manufacturer’s instruction.
Western blot analysis
Cells in culture were lysed using M-PER reagents (Pierce,
Rockford, IL, USA) in the presence of Cocktail protease in-
hibitor (Pierce). The concentration was measured by a
BCA Protein Assay Kit (Pierce). Fifty micrograms protein
samples were resolved with 5× Lane Marker Reducing
Sample Buffer (Pierce), electrophoresed in 10% SDS-PAGE
and transferred onto PVDF membranes (Bio-Rad Labora-
tories, CA, USA). Labeled bands were detected using the
ECL chemiluminescent kit (Pierce). Rabbit polyclonal anti-
NASP (1:1000, Abcam, Cambridge, UK) and mouse mono-
clonal anti-GAPDH (1:10000, Kangchen, Shanghai, China)
were used.
Retroviral transfection for stable cell lines
A genomic region including the primary transcript of
miR-29c was cloned into the EcoRI-Xhol modified
pMSCV-GW-RfA-PGK-EGFP retroviral vector, no insert
vector as a control. HEK 293 T cells (1 × 106 cells/well)
were seeded in 6-well plates 24 h prior to transfection,
2 μg of retroviral construct containing either miR-29c or
miR-control, 2 μg of gag/pol and 2 μg of VSVG were
cotransfected into HEK 293 T cells using 18 μl
FuGENE6 HD (Roche, Indianapolis, IN, USA) in each
well. At 48 and 72 h post-transfection, viruses were har-
vested and spin infected at 1500 rpm for 30 min at room
temperaturewith 8 μg/ml of polybrene. GFP positive
cells were sorted by flow cytometry and named RV-miR-
29c and RV-miR-control, respectively.
Tumor xenograft model
SGC-7901 cells (100 μl, 1 × 106 cells) infected with RV-
miR-29c or RV-miR-control were injected into the right
flank region of 4-week-old male nude mice (Institute of
Zoology, Chinese Academy of Sciences, Shanghai, China).
Each group had five mice. Tumor volume was measured
with caliper and calculated using the following for-
mula: volume = (length × width2)/2. Mice were euthanized
4 weeks after injection and tumor nodules were removed
and weighted. After tumor excision, the tumor nodules
were fixed in 10% buffered formalin for further analysis.
Animal study and experimental protocol was approved by
the Institutional Animal Care and Use Committee of the
Shanghai Jiao Tong University.
Immunohistochemistry (IHC)
Blocks of formalin-fixed, paraffin-embedded mouse sub-
cutaneous tumors were used. Tissue sections (5 μm) were
deparaffinized with xylene, rehydrated in ethanol, antigen
retrieval was performed by boiling in 10 mM citrate buffer
(pH 6.0) for 30 min. After inhibition endogenous peroxid-
ase activity with 0.3% H2O2 for 10 min, sections were
blocked in 2% serum in PBS for 30 min, incubated
with Ki-67 (dilution 1:50, Dako, Carpinteria, CA, USA) or
NASP (dilution 1:100) at 4 °C overnight, followed by
secondary antibody incubation and visualized with
Envision System (Dako). Sections were counterstained
with hematoxylin.
Statistics
Experimental data were expressed as the mean ± SD.
Pearson χ2 test was applied to examine the relationship
between the miR-29c expression level and clinicopatho-
logic parameters, unpaired t test was used to analyzed
the differences between two groups. All statistical
analyses were performed using the SPSS 15.0 soft-
ware, and a P value less than 0.05 was considered
statistically significant.
Results
MiR-29c is down-regulated in gastric cancer tissues and
cell lines
To evaluate the significance of miR-29c in gastric cancer,
we first detected miR-29c expression level in 67 pairs of
gastric cancer tissues and adjacent normal tissues by
qPCR. As shown in Fig. 1a and b, miR-29c expression
level was significantly down-regulated in gastric cancer
tissues compared with matched normal tissues (P < 0.001).
The expression levels of miR-29c in nine gastric cancer
cell lines and one immortalized normal gastric mucosal
epithelial cell line GES-1 were also assessed (Fig. 1c). All
of the gastric cancer cell lines have a significant decrease
in the levels of miR-29c compared with GES-1. Signifi-
cantly, SGC-7901 expressed the lowest level of miR-29c
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among these cell lines. Together, these data indicate
that miR-29c was prominently down-regulated in gas-
tric cancer.
Moreover, we analyzed the relationship between the
expression level of miR-29c and the clinicopathological
parameters in the 67 cases. Among these samples, 80.6%
(54/67) of tumor tissues showed down-regulation of
miR-29c in comparison to matched normal tissues (rela-
tive expression ratio < 1.0). Furthermore, 47.8% (32/67)
of tumor tissues displayed more significant down-
regulation of miR-29c (relative expression ratio < 0.5).
On the basis of relative expression ratio < 0.5, the 67
gastric cancer tissues were classified into two groups:
low-miR-29c group (n = 32) and high-miR-29c group
(n = 35). Unfortunately, miR-29c expression level did not
show any correlation with gender, age, location, Borrmann
classification, differentiation, local invasion, lymph node
metastasis or TNM stage (Additional file 1: Table S1).
miR-29c inhibits gastric cancer cell proliferation in vitro
Based upon the analysis of the expression level of miR-29c
in gastric cancer tissues and cell lines, we hypothesized
that miR-29c re-expression might lead to an inhibition of
cell growth. SGC-7901 was chosen for subsequent func-
tional studies because of its lowest expression level of
miR-29c. To test if miR-29c overexpression decreases cell
viability, SGC-7901cells were transfected with 100 nM
miR-29c mimics, and miR-29c was elevated by 17.2 ± 2.19
fold compared to miR-control (P = 0.009, Fig. 2a). The ef-
ficiency of transfection was also monitored by using a
Cy3-labeled pre-miR negative control (Additional file 2:
Figure S1A). As hypothesized, we found that miR-29c
overexpression leads to cell growth inhibition through
CCK-8 cell proliferation assay (Fig. 2b). Further study of
cell viability using colony formation assay also exhibited
an obvious attenuation of cell growth in SGC-7901 cells
transfected with miR-29c mimics (28.4 ± 2.70 vs. 15.4 ±
4.22, P < 0.001, Fig. 2c and d). Taken together, these results
suggest that miR-29c exerts a growth inhibitory effect in
gastric cancer cells.
miR-29c promotes gastric cancer cell apoptosis and
induces cell cycle arrest in G1/G0 phase
Next, the effects of miR-29c on cell apoptosis and cell cycle
were examined through flow cytometry. Our data showed
that the apoptotic rate was significantly increased in cells
transfected with miR-29c mimics in comparison with miR-
control (15.2% ± 1.29% vs. 3.02% ± 0.297%, P = 0.0025,
Fig. 3a). Cell cycle analysis showed the percentage of cells
in G1/G0 phase was increased from 48.1% ± 1.20% to
55.9% ± 2.99% (P = 0.032, Fig. 3b). The percentage of cells
in S phase and G2/M phase appeared to reduce in miR-
Fig. 1 Expression of miR-29c was down-regulated in gastric cancer tissues and cell lines. a miR-29c expression in 67 pairs of gastric cancer tissues
compared to matched adjacent normal tissues. miRNA expression of each sample was normalized to U6 expression. Normalized miRNA tumor
expression was compared to normalized normal sample. b Expression of miR-29c in 67 pairs of gastric cancer and normal tissues. c miR-29c
expression in GES-1 and nine gastric cancer cell lines (SNU-1, SNU-16, AGS, MKN-45, MKN-28, BGC-823, NCI-N87, KATOIII and SGC-7901). Data
shown are the mean ± SD of three independent experiments. * P < 0.05, ** P < 0.01, *** P < 0.001
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Fig. 2 miR-29c inhibited gastric cancer cell proliferation. a miR-29c expression level in SGC-7901 transfected with miR-control or miR-29c detected
by qPCR. b CCK-8 assay was performed to monitor the proliferation of SGC-7901 treated with miR-control or miR-29c. c, d Cell proliferation was
measured by colony formation assay. Data are represented as the mean ± SD from three independent experiments. ** P < 0.01, *** P < 0.001
Fig. 3 The effect of miR-29c on SGC-7901 apoptosis and cell cycle progression. a Representative histograms depicting apoptosis in SGC-7901 cells
transfected with miR-29c or miR-control. Cells staining positive for Annexin V-FITC and negative for PI at 48 h after transfection were considered
to have undergone apoptosis. b Representative histograms depicting cell cycle profiles of SGC-7901 cells transfected with miR-29c or miR-control.
The results are shown as mean ± SD from three independent experiments. * P < 0.05, ** P < 0.01
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29c overexpression cells, however, these differences had no
statistically significance (Fig. 3b). The results indicate that
overexpression of miR-29c can induce gastric cancer cell
apoptosis and cell cycle arrest in G1/G0 phase, which con-
tributes to growth inhibitory properties of miR-29c.
To confirm the biological function of miR-29c, we also
transfected SNU-1 cells with miR-29c inhibitor (anti-
miR-29c). In contrast, inhibition of miR-29c in SNU-1
promoted cell proliferation, reduced cell apoptosis and
decreased cell percentage in G1/G0 phase (Additional
file 3: Figure S2).
miR-29c targets NASP directly
To explore the target gene of miR-29c by which inhibits
cell proliferation in gastric cancer. We searched candi-
date target genes of miR-29c through TargetScan, miR-
Base Target and PicTar algorithms. Among the predicted
targets, NASP, required for DNA replication, cell prolif-
eration and normal cell cycle progression [11], was
chosen as one of the targets of miR-29c and further
identified two potential binding sites within its 3′UTR
which located at position 289–296 (8-mer) and position
348–354 (7-mer), respectively (Fig. 4a).
To confirm the direct binding effect of miR-29c to
NASP 3′UTR, dual luciferase report assay was per-
formed in HEK 293 T. Two regions of NASP 3′UTR
each containing one putative miR-29c binding site
(named as WT1 and WT2) and their corresponding mu-
tation types (named as MUT1 and MUT2) were cloned
into the pMIR-Report luciferase vector (Fig. 4b). These
constructs were cotransfected with miRNA mimics and
pRL-TK into HEK 293 T cells, and luciferase activities
were measured. For WT1 reporter transfected with miR-
29c mimics, the luciferase activity was significantly de-
creased (P < 0.05), while for WT2 reporter, the activity
was not affected after miR-29c transfection. Moreover,
the repression of luciferase activity caused by miR-29c
overexpression was clearly abrogated by MUT1 (Fig. 4c).
These data indicate that miR-29c may target NASP
through the 8-mer seeding region of 3′UTR.
Furthermore, we checked the influence of miR-29c on
the expression of NASP by dectecting the protein and
mRNA level of NASP after transfecting miR-29c mimics
or miR-control. Western blot analysis displayed that an
enforced miR-29c expression resulted in a decrease of
NASP protein level in SGC-7901 cells (Fig. 4d). However,
there was no effect on NASP mRNA level as detected by
qPCR (Fig. 4e). These data demonstrate that miR-29c re-
presses NASP expression at the post-transcriptional level,
likely through directly targeting the 3′UTR of NASP.
miR-29c suppresses tumorigenicity in vivo
Next, we examined whether miR-29c overexpression
could suppress the tumor growth in vivo. SGC-7901
cells mediated with RV-miR-29c or SGC-7901-RV-miR-
control retrovirus were obtained as described in the Ma-
terial and methods. The percentage of GFP positive cells
was over 90% in both cell lines (Additional file 2: Figure
S1B). And the miR-29c expression level was 129.7 ±
12.24 fold higher in SGC-7901-RV-miR-29c cells than
that in control cells (P = 0.003, Fig. 5a). The result from
Western blot was confirmed that the protein level of
NASP was indeed down-regulated in SGC-7901-RV-
miR-29c cells (Fig. 5b), and the NASP mRNA level still
had no change after RV-miR-29c infection (Fig. 5c).
These two groups of cells were injected subcutaneously
into the right flank of nude mice and tumor nodules
were monitored. After 4 weeks, the mice were sacrificed
and the tumor nodules were weighted. As shown in
Fig. 5d, tumors grew slower in the SGC-7901-RV-miR-
29c group than those in the control group. The average
tumor volume in SGC-7901-RV-miR-29c group at day
25 and day 28 was significantly smaller compared with
the miR-control group (Fig. 5e). Similarly, the tumor
weight in SGC-7901-RV-miR-29c group was significantly
less than that from the miR-control group (1.550 ±
0.530 g vs. 0.860 ± 0.265 g, P = 0.041, Fig. 5f ).
To assess whether tumor growth inhibition in mice
injected with SGC-7901-RV-miR-29c cells was partly
caused by the suppression of proliferation, IHC analysis
of Ki-67 antigen was performed. As Fig. 5g shown, the
percentage of Ki-67 positive cells was much lower in the
nodules derived from SGC-7901-RV-miR-29c group than
that in the control group (34.7% ± 9.29% vs. 71.3% ±
4.16%, P = 0.011). So the reduced tumor growth in mice
was, at least in part, because of decreased proliferation
which caused by miR-29c overexpression. Moreover, the
tumor derived from RV-miR-29c showed weeker immu-
nohistochemical staining of NASP than that derived from
the control group (Fig. 5h). Therefore, miR-29c can inhibit
tumorigenicity in vivo.
miR-29c expression negatively correlates with NASP
protein expression in gastric cancer cell lines
Next, we evaluated NASP protein level in GES-1 and
nine gastric cancer cell lines by Western blot analysis.
Most of the gastric cancer cell lines have an increase in
the levels of NASP protein level compared with GES-1
(Fig. 6a). Among them, SGC-7901, MKN-45, MKN-28
and BGC823 expressed much higher levels of NASP
while these cell lines exhibited lower miR-29c expression
levels (Fig. 1c). Furthermore, there was a negative
correlation between miR-29c and NASP protein level
(r = −0.644, P = 0.044, Fig. 6b). Moreover, we measured
miR-29c expression and NASP protein level in 4 pairs of
gastric cancer and matched normal tissues. An inverse cor-
relation was observed between miR-29c and NASP protein
expression level, as shown in Additional file 2: Figure S1C.
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Knockdown of NASP elicits the phenotypes caused by
miR-29c overexpression in gastric cancer cells
Since miR-29c down-regulated NASP to suppress cell
proliferation, induce cell apoptosis and cause cell cycle
arrest in G1/G0, it is reasoned that specific knockdown
of NASP could elicit similar phenotypes induced by
miR-29c in gastric cancer. To test it, SGC-7901 were
transfected with NASP siRNA firstly, and the knockdown
efficiency was confirmed by qPCR and Western blot
(Additional file 2: Figure S1D). Among three siRNAs of
NASP, siNASP-337 was chose for further analysis because
of its highest knockdown efficiency (Fig. 6c). As expected,
proliferation assay showed that knockdown of NASP have
an obvious inhibitory effect on SGC-7901 cell growth
(Fig. 6d). Cell apoptosis rate raised from 2.64% ± 0.502%
to 14.1% ± 1.50% after transfection with siNASP-337
(P = 0.003, Fig. 6e). Moreover, cell cycle progression
was also arrested in G1/G0 phase (56.6% ± 0.785% vs.
50.2% ± 1.29%, P = 0.042, Fig. 6f ). Further, NASP was
overexpressed in SGC-7901 cells and then transfected
with miR-29c mimics, the inhibitory effect of miR-29c
on cell proliferation was partially reversed, and the
Fig. 4 miR-29c targeted the 3′UTR of NASP and the effect on NASP expression. a Schematic graph of the putative binding sites of miR-29c in the
NASP 3′UTR predicted by TargetScan. b Construction of the reporter plasmids. WT1, MUT1, WT2 and MUT2 were inserted into downstream of
luciferase of pMIR-reporter vector. c Dual luciferase report assays were performed on HEK 293 T cells. d, e Forty-eight hours after miR-29c mimics
or miR-control transfection on SGC-7901, NASP protein level and mRNA level was measured by Western blot analysis and qPCR, respectively. Each
bar represents mean ± SD from three independent experiments. * P < 0.05
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progressions toward apoptosis and G1/G0 cell cycle
arrest were also hindered (Additional file 4: Figure S3).
Taken together, these data provide evidence that the
function of miR-29c inhibit cell proliferation in gas-
tric cancer is at least partially through targeting
NASP.
Discussion
Accumulating studies have focused on the role of miR-
NAs play in regulating cell proliferation process in gas-
tric cancer. MiR-29c has been shown to be down-
regulated in gastric cancer, but the downstream targets
differ and it is not clear how miR-29c mediates cell
Fig. 5 miR-29c inhibited tumorigenicity and proliferation in vivo. a qPCR analysis of miR-29c expression levels in SGC-7901-RV-miR-control and
SGC-7901-RV-miR-29c cells. b Western blot analysis of NASP in SGC-7901-RV-miR-control and SGC-7901-RV-miR-29c cells. c qPCR analysis of NASP
mRNA levels in SGC-7901-RV-miR-control and SGC-7901-RV-miR-29c cells. d Photographs of tumors derived from nude mice injected with SGC-
7901-RV-miR-control and SGC-7901-RV-miR-29c cells. e Tumor growth kinetics in two groups of nude mice. f Average weight of tumor derived
from nude mice injected with SGC-7901-RV-miR-control and SGC-7901-RV-miR-29c cells. g Representive photographs of immunohistochemical
analysis of Ki-67 and its proliferation index in tumor xenografts. h Representive photographs of immunohistochemical analysis of NASP in tumor
xenografts. Data are shown as mean ± SD of three independent experiments. * P < 0.05, ** P < 0.01
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responses in varying cell contexts. Han et al. reported
that miR-29c involved in the initiation of gastric carcino-
genesis by directly targeting ITGB1 [12]. They found
restoration of miR-29c inhibits cell proliferation, adhe-
sion, invasion and migration in gastric cancer. Another
research group verified the downregulation of miR-29c
in gastric cancer patients and assessed proliferation and
colony formation ability of miR-29c by targeting RCC2
[13]. It was showed that all the members of miR-29 fam-
ily were down-regulated in gastric cancer and miR-29c
Fig. 6 NASP knockdown elicits the phenotypes of miR-29c in gastric cancer cells. a NASP protein levels in GES-1 and 9 gastric cancer cell lines.
The relative intensity was normalized to GES-1 and determined by Image J. b Scatter plot of miR-29c expression versus NASP protein expression
in GES-1 and 9 gastric cancer cell lines. c Western blot analysis in SGC-7901 cells transfected with siNASP-337 or siRNA control to evaluate NASP
knockdown efficiency. d CCK-8 proliferation assay was performed in SGC-7901 cells transfected with siNASP-337 or siRNA control. e Apoptosis
assay in SGC-7901 cells transfected with siNASP-337 or siRNA control by flow cytometry. f Cell cycle progression was assessed by flow cytometry
in SGC-7901 cells transfected with siNASP-337 or siRNA control. Data are represents as mean ± SD from three independent experiments.
* P < 0.05, ** P < 0.01, *** P < 0.001
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was more significant as a signature miRNA than miR-
29a or 29b for gastric cancer. Furthermore, they dem-
onstrated that miR-29 family directly targeted CCND2
and MMP2 to influence gastric cancer progression
[14]. It also has been reported that miR-29c regulates
the expression of many oncogenes, such as CDK6,
CDC42, p85α, DNMT3a and DNMT3b in other types
of cancers [6, 15, 16].
In present study, we indicate that miR-29c acts as a
tumor suppressor by suppressing cell growth through
CCK-8 and colony formation assays, promotes apoptosis
and arrests cell cycle at G1/G0 stage by targeting NASP.
Furthermore, the down-regulation of NASP can elite the
phenotypes caused by miR-29c. As a histone chaperone,
NASP binds both core and linker histones that is proved
to present in all dividing cells [17]. Two splice variants
of NASP have been reported: testicular NASP (tNASP),
which is mainly expressed in testis, stem cells, embry-
onic tissues and malignant tumors; somatic NASP
(sNASP), which exists in all somatic mitosis cells. Both
types of NASP specifically bind to histone H1, H3 and
H4 and affect chromatin assembly, lead to the associ-
ation with DNA replication, cell proliferation and cell
cycle progression [18]. Previous studies have investigated
the role of NASP in renal cell carcinoma [19]. Fang et al.
showed that tNASP has a relative high level in human
renal cell carcinoma and tNASP knockdown effectively
suppresses cell proliferation and induces G1 phase arrest
through ERK/MAPK signaling pathway. Additional
studies indicated that depletion of tNASP inhibited cell
proliferation and promoted apoptosis in prostate cancer
cells [20]. However, the mechanisms that result in ele-
vated NASP expression level are still unclear. Our study
suggests one mechanism that contributes to the elevated
NASP levels in tumors is a deregulation of miR-29c
and further supports targeting NASP as a therapeutic
strategy in gastric cancer.
Our study also demonstrates that the expression level
of miR-29c is lower in 67 cases of gastric cancer com-
pared with matched normal tissues, and the expression
also decreases in nine gastric cancer cell lines versus
GES-1. The relationship between the miR-29c expres-
sion level and the clinicopathological factors in human
gastric cancer samples was further analyzed. However,
miR-29c expression level did not show any correlation
with the clinicopathological parameters. It is consistent
with the result of our previous study [21]. Among 15
candidate miRNAs selected from microRNA array, miR-
29c showed no correlation with the clinicopathological
features assessed by qPCR in 40 pairs of gastric cancer
samples. Liu et al. evaluated the role of miR-29c, miR-
124, miR-135a and miR-148a in predicting lymph node
metastasis and tumor stage in gastric cancer, they
showed a week relationship between miR-29c expression
level and gastric cancer stage on the basis of P = 0.049 in
60 gastric cancer tissues [22]. More samples and fur-
ther studies are needed to disclosure the relationship
between miR-29c and the clinicopathological features
in gastric cancer.
Conclusions
In summary, we have clarified a novel pathway regulat-
ing cell proliferation in gastric cancer, which is, miR-29c
inhibits cell proliferation, promotes apoptosis and arrests
cell cycle at G1/G0 phase by targeting NASP. Our study
highlights the potential apply of miR-29c as an early bio-
marker and therapeutic target of gastric cancer.
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